Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more

Recent & Breaking News (NDAQ:MCRB)

Seres Therapeutics to Participate in Three Upcoming November Conferences

Business Wire November 8, 2017

Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress

Business Wire November 8, 2017

Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate

Business Wire November 7, 2017

Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017

Business Wire November 2, 2017

Sigilon Therapeutics Appoints Eric Shaff to Board of Directors

PR Newswire November 1, 2017

Mid-Afternoon Market Update: Dow Gains 130 Points; CyberOptics Shares Plunge

Benzinga.com  October 2, 2017

12 Biggest Mid-Day Losers For Monday

Benzinga.com  October 2, 2017

Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Posts Wider-Than-Expected Loss

Benzinga.com  October 2, 2017

Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis

Business Wire October 2, 2017

Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference

Business Wire August 31, 2017

Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress

Business Wire August 3, 2017

Investor Network: Seres Therapeutics Inc to Host Earnings Call

Accesswire August 3, 2017

Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference

Business Wire August 2, 2017

Seres Therapeutics to Host Second Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2017

Business Wire July 27, 2017

Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer

Business Wire July 10, 2017

Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection

Business Wire June 12, 2017

Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference

Business Wire June 6, 2017

Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis

Business Wire June 5, 2017

Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress

Business Wire May 4, 2017

Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences

Business Wire May 1, 2017